AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33374368 — intervention group
Group type: EXPERIMENTAL
Intervention: Nighttime green walking
Number of subjects: 48
Study 33374368 — intervention group
Group type: COMPARATOR
Intervention: Nighttime urban walking
Number of subjects: 48
Study 36068576 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching Recovery Techniques (TRT)
Number of subjects: 76
Study 36068576 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 76
Study 34444820 — intervention group
Group type: EXPERIMENTAL
Intervention: NVP‐1704
Number of subjects: 156
Study 34444820 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 36466482 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment plus computer-generated individualized feedback letters
Number of subjects: 1646
Study 36466482 — intervention group
Group type: COMPARATOR
Intervention: Assessment only
Number of subjects: 1646
Study 33006446 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass fiber posts
Number of subjects: 50
Study 33006446 — intervention group
Group type: COMPARATOR
Intervention: Control group (no glass fiber posts)
Number of subjects: 50
Study 33917587 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-mm short implants
Number of subjects: 12
Study 33917587 — intervention group
Group type: COMPARATOR
Intervention: 10-mm standard implants
Number of subjects: 12
Study 33001139 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dexmedetomidine (700 mcg)
Number of subjects: 15
Study 33001139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 35899204 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided internet-based cognitive behavioral therapy for insomnia (iCBT-I; i-Sleep)
Number of subjects: 96
Study 35899204 — intervention group
Group type: COMPARATOR
Intervention: Control group (sleep diary monitoring)
Number of subjects: 96
Study 36112820 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person education through DREAMS health seminar series
Number of subjects: 130
Study 36112820 — intervention group
Group type: COMPARATOR
Intervention: Remote (independent reading with telephone support)
Number of subjects: 130
Study 33978924 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy (PT)
Number of subjects: 40
Study 33978924 — intervention group
Group type: COMPARATOR
Intervention: Control (CT)
Number of subjects: 40
Study 33069109 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-day stimulus–response compatibility (SRC) approach bias modification treatment
Number of subjects: 48
Study 33069109 — intervention group
Group type: COMPARATOR
Intervention: Corresponding SRC pseudomodification training
Number of subjects: 48
Study 33136517 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2 Inhibition in Combination with Loop Diuretics
Number of subjects: 0
Study 35580546 — intervention group
Group type: EXPERIMENTAL
Intervention: 4F-PCC for factor Xa inhibitors
Number of subjects: 221
Study 35580546 — intervention group
Group type: COMPARATOR
Intervention: 4F-PCC for warfarin
Number of subjects: 221
Study 35580546 — intervention group
Group type: EXPERIMENTAL
Intervention: 4F-PCC for both groups
Number of subjects: 221
Study 33413599 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous warfarin administration
Number of subjects: 0
Study 33413599 — intervention group
Group type: COMPARATOR
Intervention: Heparin bridge therapy
Number of subjects: 0
Study 32152915 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi‐compartmental biorelevant dissolution testing model
Number of subjects: 0
Study 32152915 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation of oral absorption using GastroPlus™ and dissolution data
Number of subjects: 0
Study 32152915 — intervention group
Group type: EXPERIMENTAL
Intervention: Characterization of precipitates in the intestinal compartment
Number of subjects: 0
Study 33511988 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light treatment (10,000 lux for 30 min/day)
Number of subjects: 69
Study 33511988 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (inactivated negative ion generator)
Number of subjects: 69
Study 34319575 — intervention group
Group type: EXPERIMENTAL
Intervention: 96-case Perceptual Learning Module (PLM)
Number of subjects: 52
Study 34319575 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PLM)
Number of subjects: 52
Study 34319575 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups at six months
Number of subjects: 52
Study 32207040 — intervention group
Group type: EXPERIMENTAL
Intervention: Mendelian randomization (MR)
Number of subjects: 0
Study 32207040 — intervention group
Group type: COMPARATOR
Intervention: Conventional observational epidemiology
Number of subjects: 0
Study 36536711 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard high calorie drink with ginger extract addition
Number of subjects: 40
Study 36536711 — intervention group
Group type: COMPARATOR
Intervention: Standard high calorie drink
Number of subjects: 40
Study 32236950 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab + chlorambucil
Number of subjects: 0
Study 32236950 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil monotherapy
Number of subjects: 0
Study 34886571 — intervention group
Group type: EXPERIMENTAL
Intervention: Planning Health in School programme (PHS‐pro)
Number of subjects: 504
Study 36378675 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based intervention program
Number of subjects: 49
Study 36378675 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face interventions (control group)
Number of subjects: 49
Study 35710449 — intervention group
Group type: EXPERIMENTAL
Intervention: eSyM (electronic symptom management program) integrated into the Epic EHR system
Number of subjects: 0
Study 33757606 — intervention group
Group type: EXPERIMENTAL
Intervention: anodal tDCS over the right IFG at 1.25 mA combined with inhibitory control training
Number of subjects: 100
Study 33757606 — intervention group
Group type: COMPARATOR
Intervention: sham tDCS
Number of subjects: 100
Study 32069129 — intervention group
Group type: EXPERIMENTAL
Intervention: RadioEar DD65v2 audiometric headphones
Number of subjects: 25
Study 36441246 — intervention group
Group type: EXPERIMENTAL
Intervention: Ronch®AP palatal device
Number of subjects: 52
Study 36441246 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 52
Study 34016112 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone
Number of subjects: 0
Study 34016112 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34950944 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive screening for TB and HIV
Number of subjects: 1032
Study 34950944 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC; clinic referral letters)
Number of subjects: 1032
Study 33823062 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational dusts
Number of subjects: 2514
Study 33823062 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical vapors
Number of subjects: 2514
Study 33823062 — intervention group
Group type: EXPERIMENTAL
Intervention: Exhausts/smokes
Number of subjects: 2514
Study 33823062 — intervention group
Group type: EXPERIMENTAL
Intervention: Acids/alkalis
Number of subjects: 2514
Study 32028117 — intervention group
Group type: EXPERIMENTAL
Intervention: GA 40 mg/mL three-times-weekly (TIW)
Number of subjects: 789
Study 32028117 — intervention group
Group type: COMPARATOR
Intervention: GA 20 mg/mL once-daily (QD)
Number of subjects: 789
Study 35365063 — intervention group
Group type: EXPERIMENTAL
Intervention: BTT with LVAD
Number of subjects: 7759
Study 34526072 — intervention group
Group type: EXPERIMENTAL
Intervention: i-PUSH program implementation
Number of subjects: 240
Study 34526072 — intervention group
Group type: EXPERIMENTAL
Intervention: LEAP training tool
Number of subjects: 240
Study 34526072 — intervention group
Group type: EXPERIMENTAL
Intervention: M-TIBA health wallet
Number of subjects: 240
Study 34526072 — intervention group
Group type: COMPARATOR
Intervention: Control group (no i-PUSH implementation)
Number of subjects: 240
Study 32203978 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab (50, 150, or 300 mg) subcutaneously once every 3 months
Number of subjects: 8683
Study 32203978 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab
Number of subjects: 8683
Study 32203978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8683
Study 35452919 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy intervention
Number of subjects: 604
Study 34108261 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus + BNC105P
Number of subjects: 82
Study 34108261 — intervention group
Group type: COMPARATOR
Intervention: Everolimus alone
Number of subjects: 82
Study 34108261 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus ± BNC105P
Number of subjects: 82
Study 34108261 — intervention group
Group type: COMPARATOR
Intervention: Everolimus
Number of subjects: 82
Study 35121250 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery Rescripting (IR)
Number of subjects: 41
Study 35121250 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Restructuring (CR)
Number of subjects: 41
Study 33355633 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind My Mind (MMM)
Number of subjects: 396
Study 33355633 — intervention group
Group type: COMPARATOR
Intervention: Management as Usual (MAU)
Number of subjects: 396
Study 35572837 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion instrument combined with intermediate frequency electrostatic therapy
Number of subjects: 200
Study 35572837 — intervention group
Group type: COMPARATOR
Intervention: Medium-frequency treatment (Control)
Number of subjects: 200
Study 32638420 — intervention group
Group type: EXPERIMENTAL
Intervention: Price increase framed as a health-related, earmarked tax
Number of subjects: 603
Study 32638420 — intervention group
Group type: COMPARATOR
Intervention: Price increase not framed as a tax
Number of subjects: 603
Study 36324229 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon β‐1a (7.5‐30 μg)
Number of subjects: 84
Study 36324229 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon β‐1a (31.25‐125 μg)
Number of subjects: 84
Study 36324229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 32095954 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth treatment for urinary incontinence (UI)
Number of subjects: 373
Study 32475672 — intervention group
Group type: EXPERIMENTAL
Intervention: Sericea lespedeza (SL) diet
Number of subjects: 4
Study 32475672 — intervention group
Group type: COMPARATOR
Intervention: Alfalfa (ALF) diet
Number of subjects: 4
Study 32475672 — intervention group
Group type: COMPARATOR
Intervention: Birdsfoot trefoil (BFT) diet
Number of subjects: 4
Study 32475672 — intervention group
Group type: COMPARATOR
Intervention: Crown vetch (CV) diet
Number of subjects: 4
Study 35382796 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop insulin delivery (CamAPS FX application, Dana Diabecare RS insulin pump)
Number of subjects: 124
Study 35382796 — intervention group
Group type: COMPARATOR
Intervention: Continuous glucose monitoring (CGM) with usual insulin delivery (Dexcom G6)
Number of subjects: 124
Study 35382796 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop insulin delivery
Number of subjects: 124
Study 34727936 — intervention group
Group type: EXPERIMENTAL
Intervention: Naprapathy
Number of subjects: 78
Study 33551858 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based intervention program comprising 6 to 8 semi-structured sessions over a period of about 6 months.
Number of subjects: 0
Study 33551858 — intervention group
Group type: COMPARATOR
Intervention: Control condition: treatment as usual.
Number of subjects: 0
Study 34669645 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-Directed Fluid Therapy (GDFT)
Number of subjects: 40
Study 34669645 — intervention group
Group type: COMPARATOR
Intervention: Conventional fluid strategy
Number of subjects: 40
Study 33212067 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dose CYD-TDV regimen (0.5 mL each dose, administered subcutaneously at months 0, 6, and 12)
Number of subjects: 1050
Study 33212067 — intervention group
Group type: COMPARATOR
Intervention: Three-dose CYD-TDV regimen (0.5 mL each dose, administered subcutaneously at months 0, 6, and 12)
Number of subjects: 1050
Study 33212067 — intervention group
Group type: COMPARATOR
Intervention: Two-dose placebo (administered at months 0 and 6) and one dose of CYD-TDV (administered at month 12)
Number of subjects: 1050
Study 33212067 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety assessment for all groups
Number of subjects: 1050
Study 32792244 — intervention group
Group type: EXPERIMENTAL
Intervention: SSS07, a humanized rabbit anti-human TNF alpha antibody
Number of subjects: 0
Study 34642104 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Number of subjects: 40
Study 34642104 — intervention group
Group type: COMPARATOR
Intervention: Sham auricular acupuncture (Control)
Number of subjects: 40
Study 33731058 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (20 mg/kg)
Number of subjects: 450
Study 33731058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study 32227753 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive treatment strategy
Number of subjects: 4617
Study 32227753 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment strategy
Number of subjects: 4617
Study 33383371 — intervention group
Group type: EXPERIMENTAL
Intervention: Babao Dan (BBD) plus lactulose
Number of subjects: 62
Study 33383371 — intervention group
Group type: COMPARATOR
Intervention: Lactulose alone
Number of subjects: 62
Study 33066009 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole eggs (3 eggs/day)
Number of subjects: 23
Study 33066009 — intervention group
Group type: COMPARATOR
Intervention: Choline supplement (choline bitartrate, 400 mg choline/day)
Number of subjects: 23
Study 33066009 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 23
Study 35169841 — intervention group
Group type: EXPERIMENTAL
Intervention: Variant of uncertain significance
Number of subjects: 0
Study 35169841 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic diagnosis affecting neurodevelopment but not acute survival
Number of subjects: 0
Study 35169841 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic etiology of disease
Number of subjects: 0
Study 35169841 — intervention group
Group type: COMPARATOR
Intervention: Pending genetic testing result
Number of subjects: 0
Study 33631714 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonleisure-time physical activity guidance (NLTPAG)
Number of subjects: 33
Study 32941098 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel interventions for severe asthma; specific interventions not detailed; crossover design with each participant receiving up to five interventions and at least one placebo.
Number of subjects: 0
Study 32941098 — intervention group
Group type: COMPARATOR
Intervention: Placebo; at least one placebo administered to participants.
Number of subjects: 0
Study 35106632 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystine and glutamine supplementation
Number of subjects: 16
Study 35106632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 33271633 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexcom G6 continuous glucose monitoring (CGM)
Number of subjects: 14
Study 33271633 — intervention group
Group type: COMPARATOR
Intervention: Standard care with a glucometer (control)
Number of subjects: 14
Study 34098409 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery-based cognitive behavioural intervention (ICBI)
Number of subjects: 56
Study 34098409 — intervention group
Group type: COMPARATOR
Intervention: Non-directive supportive therapy (NDST)
Number of subjects: 56
Study 32549100 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lidocaine group (10% lidocaine oropharyngeal spray, five minutes before laryngoscopy and endotracheal intubation)
Number of subjects: 60
Study 32549100 — intervention group
Group type: COMPARATOR
Intervention: Control group (no lidocaine spray)
Number of subjects: 60
Study 32549100 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 35114983 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported Osteoarthritis Self‐management Program (SOASP) with self‐monitoring physical activity using a commercial wearable activity tracker (WAT) for 12 weeks, n = 86
Number of subjects: 160
Study 35114983 — intervention group
Group type: COMPARATOR
Intervention: Only the Supported Osteoarthritis Self‐management Program (SOASP) for 12 weeks, n = 74
Number of subjects: 160
Study 33216632 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean Red Ginseng (3 g per day for 12 weeks)
Number of subjects: 55
Study 33216632 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 12 weeks)
Number of subjects: 55
Study 33216632 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean Red Ginseng
Number of subjects: 55
Study 32680803 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic singing
Number of subjects: 54
Study 32680803 — intervention group
Group type: EXPERIMENTAL
Intervention: General singing
Number of subjects: 54
Study 32680803 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 54
Study 33197648 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized coaching program at home (EG)
Number of subjects: 83
Study 33197648 — intervention group
Group type: COMPARATOR
Intervention: Usual care control (CG)
Number of subjects: 83
Study 34057279 — intervention group
Group type: EXPERIMENTAL
Intervention: MNM covering stent (MNM group, n = 25)
Number of subjects: 52
Study 34057279 — intervention group
Group type: COMPARATOR
Intervention: Any commercially available stent (DES group, n = 27)
Number of subjects: 52
Study 36297060 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketone monoester supplement (KME) 25 g
Number of subjects: 9
Study 36297060 — intervention group
Group type: COMPARATOR
Intervention: Non‐caloric placebo (PLAC)
Number of subjects: 9
Study 33865741 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-procedural IVUS-based regression model
Number of subjects: 618
Study 33865741 — intervention group
Group type: EXPERIMENTAL
Intervention: Convolutional neural network and mask image-derived features
Number of subjects: 618
Study 34216477 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent-Scanning Continuous Glucose Monitoring (isCGM) combined with structured education
Number of subjects: 104
Study 34216477 — intervention group
Group type: COMPARATOR
Intervention: Conventional self-monitoring of blood glucose (SMBG)
Number of subjects: 104
Study 35294320 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume high-intensity interval training (LV-HIIT) sessions (10 x 60 s at 100% of Vmax)
Number of subjects: 24
Study 35294320 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume high-intensity interval training (LV-HIIT) sessions (20 x 30 s at 100% of Vmax)
Number of subjects: 24
Study 32342648 — intervention group
Group type: EXPERIMENTAL
Intervention: LIGHT (20–30 repetition maximum)
Number of subjects: 26
Study 32342648 — intervention group
Group type: EXPERIMENTAL
Intervention: HEAVY (6–10 repetition maximum)
Number of subjects: 26
Study 32342648 — intervention group
Group type: COMPARATOR
Intervention: LIGHT and HEAVY training programs
Number of subjects: 26
Study 34750146 — intervention group
Group type: EXPERIMENTAL
Intervention: 81 mg ASA
Number of subjects: 95
Study 34750146 — intervention group
Group type: EXPERIMENTAL
Intervention: 325 mg ASA
Number of subjects: 95
Study 34750146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 33813863 — intervention group
Group type: COMPARATOR
Intervention: Control arm patients with follow-up imaging at 2-8 hours without substantial recanalization and baseline Alberta Stroke Program Early CT Score ≥9
Number of subjects: 43
Study 33894540 — intervention group
Group type: EXPERIMENTAL
Intervention: Pythagorean Self‐Awareness Intervention (PSAI) with usual care
Number of subjects: 69
Study 33894540 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 69
Study 34766577 — intervention group
Group type: EXPERIMENTAL
Intervention: Spine journal
Number of subjects: 3784
Study 34766577 — intervention group
Group type: COMPARATOR
Intervention: European Spinal Journal (EUS)
Number of subjects: 3784
Study 34766577 — intervention group
Group type: COMPARATOR
Intervention: The Spine Journal (TSJ)
Number of subjects: 3784
Study 34766577 — intervention group
Group type: COMPARATOR
Intervention: Journal of Neurosurgery ‐ Spine (JNS spine)
Number of subjects: 3784
Study 34766577 — intervention group
Group type: EXPERIMENTAL
Intervention: Corresponding authors with orthopedic specialties
Number of subjects: 3784
Study 34766577 — intervention group
Group type: COMPARATOR
Intervention: Corresponding authors who were neurosurgeons
Number of subjects: 3784
Study 34766577 — intervention group
Group type: EXPERIMENTAL
Intervention: Single institution articles
Number of subjects: 3784
Study 34766577 — intervention group
Group type: EXPERIMENTAL
Intervention: Degenerative diseases
Number of subjects: 3784
Study 34766577 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical articles
Number of subjects: 3784
Study 34766577 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analyses and randomized controlled comparative studies
Number of subjects: 3784
Study 32471514 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent pharmacist prescribing (PIP)
Number of subjects: 0
Study 32471514 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 616063492 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipsilateral breast tumour recurrence (IBTR)
Number of subjects: 1975
Study 616063492 — intervention group
Group type: EXPERIMENTAL
Intervention: ER-negative cohort
Number of subjects: 1975
Study 616063492 — intervention group
Group type: EXPERIMENTAL
Intervention: ER-positive cohort
Number of subjects: 1975
Study 616063492 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary tumor characteristics (T size, nodal status)
Number of subjects: 1975
Study 36018753 — intervention group
Group type: EXPERIMENTAL
Intervention: Dendritic cell vaccines with 0.10, 0.33, or 1.0 µg of recombinant SARS-CoV-2 spike protein, with or without GM-CSF
Number of subjects: 176
Study 36018753 — intervention group
Group type: EXPERIMENTAL
Intervention: Dendritic cell vaccines without GM-CSF
Number of subjects: 176